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A B S T R A C T
Objectives: This study was conducted to assess the prevalence of azole resistance in Aspergillus isolates
from patients with haematological malignancies or who were undergoing haematopoietic stem cell
transplantation and to identify the molecular mechanism of resistance.
Methods: In this 28-month prospective study involving 18 Italian centres, Aspergillus isolates from
surveillance cultures were collected and screened for azole resistance, and mutations in the cyp51A gene
were identified. Resistant isolates were genotyped by microsatellite analysis, and the allelic profiles were
compared with those of resistant environmental and clinical isolates from the same geographical area
that had been previously genotyped.
Results: There were 292 Aspergillus isolates collected from 228 patients. The isolates belonged mainly to
the section Fumigati (45.9%), Nigri (20.9%), Flavi (16.8%) and Terrei (4.8%). Three isolates showed
itraconazole resistance: Aspergillus fumigatus sensu stricto, Aspergillus lentulus (section Fumigati) and
Aspergillus awamori (section Nigri). The itraconazole resistance rates were 1% and 1.48% considering all
Aspergillus spp. isolates and the Aspergillus section Fumigati, respectively. The prevalence of azole
resistance among all the patients was 1.3%. Among patients harbouring A. fumigatus sensu stricto isolates,
the resistance rate was 0.79%. The A. fumigatus isolate, with the TR34/L98H mutation, was genotypically
distant from the environmental and clinical strains previously genotyped.
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2 A. Prigitano et al. / Journal of Global Antimicrobial Resistance 22 (2020) xxx–xxxConclusions: In this study, the Aspergillus azole resistance rate was 1% (3/292). In addition to A. fumigatus
sensu stricto, A. lentulus and A. awamori azole-resistant isolates were identified. Therefore, it is important
have a correct identification at the species level to address a rapid therapy better, quickly understand the
shift towards cryptic species and have an updated knowledge of the local epidemiology.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Several fungal infections in the compromised host arise from
the inhalation of spores as a consequence of environmental
exposure. Fungal colonization can be acquired in the community,
and it might evolve into an invasive infection during hospitaliza-
tion due to severe immunosuppressive treatments to which
patients are exposed [1].
Invasive aspergillosis (IA) is a severe disease in patients
with haematological malignancy and in those undergoing
haematopoietic stem cell transplantation (HSCT) and azoles,
mainly voriconazole and posaconazole, are the most widely
used antifungals in prophylaxis and targeted therapy [2]. The
difficulties of obtaining biological samples, such as via
bronchoalveolar lavage or biopsy in severely immunocompro-
mised patients who are often thrombocytopenic, limit the
possibility of culturing the fungus. For this reason, the
diagnosis of IA in haematological patients relies mainly on
indirect methods (e.g. galactomannan assay and polymerase
chain reaction) [2]. In several haematological and transplanta-
tion centres, surveillance cultures of nasal and oropharyngeal
swabs are routinely carried out because the colonization of the
upper airways represents the first step in the development of a
pulmonary infection [3,4].
The emergence of multi-azole-resistance has been recognized
worldwide with the presence of resistant Aspergillus fumigatus
environmental isolates. These appeared as a consequence of the
wide use of fungicides in agriculture and for the preservation of
wood, leather or paper [5–10]. In Italy, recent studies indicate that
azole-resistant isolates were cultured from 16.9% of soil samples
[11,12]. In particular, azole resistance in A. fumigatus is mainly
associated with several point mutations in the cyp51A gene. In the
environment, the dominant mechanism of resistance, a TR34/L98H
mutation in the cyp51A gene, is the same as the most frequent one
in azole-naïve patients, suggesting an environmental origin of
resistance in clinical isolates [13–16]. Two recent Dutch studies
have shown a variability in the frequency of azole resistance in
different patient populations: 4.5–26% in isolates from intensive
care unit (ICU) patients with a probable IA and 24.6% in isolates
from haematological patients [17,18]. In Italy, a retrospective
study conducted on a heterogeneous population of patients
reported an azole resistance rate of 6.25% in the period 1998–
2006 [19].
Azole resistance has important clinical consequences, reducing
therapeutic options and limiting the probability of effective
prophylaxis [13]. Patients with IA caused by a multiazole-resistant
strain have a mortality rate of 88% compared with 30–50% in
patients infected by a susceptible strain [7].
A 28-month, prospective multicentre study (ARTE study)
was conducted in Italy to assess the prevalence of azole
resistance in Aspergillus isolates from patients with haemato-
logical malignancies or who were undergoing HSCT. This
study was carried out to identify the molecular mechanism of
resistance, compare the genotypes of environmental and clinical
isolates from the same geographical area and correlate resistance
to demographic or behavioural variables and to antifungal
treatments.2. Methods
2.1. Isolates and patients
Aspergillus spp. clinical isolates (292) were collected in the
period September 2014 to December 2016 in 18 Italian hospitals.
The isolates were obtained through surveillance cultures in
patients with haematological diseases and HSCT recipients, mainly
from respiratory tract samples—nasal swab (124 isolates), sputum
(76 isolates), pharyngeal swab (20 isolates) and auricular swabs
(n = 2). Additionally, 24 isolates were obtained through diagnostic
procedures, such as bronchoalveolar lavage (n = 17), tracheal
aspirates (n = 6), and nasal biopsy (n = 1). For some samples, more
than one isolate was analysed as a different species or as having
different morphology.
Demographic characteristics, underlying disease, previous
antifungal treatments, smoking habits, living in rural areas and
work or recreational activity with soil exposure were collected in
an anonymized form.
2.2. Identification and screening for azole resistance
The isolates, identified from the hospital microbiology labora-
tories as Aspergillus spp. on the basis of macroscopic and
microscopic morphology, were sent to the reference laboratory
(Medical Mycology Laboratory of Department of Biomedical
Sciences for Health, Università degli Studi di Milano, Milan, Italy)
for the screening of azole resistance.
Briefly, conidia from a 3-day-old culture on Sabouraud dextrose
agar (SDA; Biolife, Milan, Italy) were suspended (ca. 0.5 McFarland
standard) in sterile distilled water added to 0.05% Tween 20 (Sigma-
Aldrich,St.Louis,MO).Thesuspensionwasinoculatedontothreeplates
containing SDA supplemented with 4 mg/L itraconazole (Sigma-
Aldrich), 1 mg/L voriconazole (Sigma-Aldrich) and 0.5 mg/L posaco-
nazole(Sigma-Aldrich)andontooneplateof  SDAusedasacontrol [19].
The plates were examined after 48 h of incubation at 37 C.
2.3. Susceptibility testing
Isolates able to grow on azole-containing agar plates were
tested by the broth microdilution method according to European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
methodology [20]. The minimal inhibitory concentration (MIC)
of itraconazole, voriconazole and posaconazole was determined
visually as the lowest concentration of the drug yielding complete
inhibition of fungal growth. Candida parapsilosis ATCC 22019 and
Candida krusei ATCC 6258 were used as quality controls. Isolates
with an MIC of itraconazole and voriconazole 4 mg/L and those
with an MIC of posaconazole 0.5 mg/L were considered resistant,
whereas those with an MIC of itraconazole and voriconazole
1 mg/L and those with an MIC of posaconazole 0.125 mg/L were
considered susceptible [21].
2.4. Genotyping testing and cyp51A sequencing
Genomic DNA was extracted from the Aspergillus spp., azole-
resistant isolates using PrepMan1 Ultra sample preparation
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were identified by amplification and sequencing of a portion of the
β-tubulin gene [11]; for the molecular identification of Aspergillus
section Nigri, primers Bt2a and Bt2b specific for the β-tubulin gene
were used [22].
To identify mutations responsible for A. fumigatus azole
resistance, the cyp51A gene promoter was amplified using primers
PA5 and PA7 [23]. The cyp51A gene was amplified as described
previously [11].
Amplicons of the cyp51A gene were sequenced using BigDyeTM
terminators (Applied Biosystems) in an ABI PRISM1 310 Genetic
Analyzer (Applied Biosystems); nucleotide sequences were ana-
lysed using Finch TV software v.1.4.0 (Geospiza; https://digital-
worldbiology.com/FinchTV). The sequence alignment of
Cyp51AF1/R3, Cyp51AF2/R2 and consensus Cyp51AF1R3/AF2R2
were determined using EMBOSS explorer (http://www. bioinfor-
matics.nl/emboss-explorer to obtain the entire sequence of the
cyp51A gene fragment (1168 bp). The Cyp51AF1/R2 sequences,
obtained from resistant strains, were aligned using the Clustal W
algorithm (https://www.ebi.ac.uk/Tools/msa/clustalou) using theFig.1. Geographical distribution of involved hospitals. Coloured points indicate the sites a
sensu stricto, orange dot; A. lentulus, green dot.cyp51A gene sequence of A. fumigatus strain 237 (GenBank
accession no. AF338659) as a wild-type reference.
2.5. Microsatellite analysis
Resistant isolates were genotyped by microsatellite analysis
using the primers STRAf3A, STRAf3B, STRAf3C, STRAf4A, STRAf4B
and STRAf4C, as previously described [24]. The allelic profiles were
compared with those of resistant isolates previously genotyped [11].
Tocomparetheresultsofclinical isolatesandenvironmental isolates,
the isolate IUM 11-0396 was used to normalize the sizes.
Microsatellite profiles were imported into GenAlEx 6.5 [25] for
Nei's genetic distance matrix calculation. MEGA software (version
4.0) [26] was used to design a dendrogram by the UPGMA
(unweighted pair group method using arithmetic averages) cluster-
ing algorithm using the distance matrix generated by GenAlEx 6.5.
3. Results
During the 28-month, prospective, multicentre cohort study, a
total of 292 Aspergillus spp. isolates from 228 haematological ort which the resistant strains were isolated: Aspergillus awamori, red dot; A. fumigatus
Table 1
Distribution of Aspergillus spp. isolates from 228 haematological or HSCT patients.
Section Species Isolates
No. %
Fumigati A. fumigatus 134 45.9
A. lentulus 1 0.3
Nigri A. niger 59 20.2
A. awamori 2 0.7
Flavi A. flavus 50 17.1
A. oryzae 6 2.0
Terrei A. terreus 14 4.8
Nidulantes A. nidulans 6 2.0
A. unguis 1 0.3
Aspergillus A. glaucus 4 1.4
Eurotium amstelodami 2 0.7
Circumdati A. ochraceus 4 1.4
Restricti A. restrictus 1 0.3
A. penicillioides 5 1.7
Versicolores A. versicolor 3 0.1
Total 292
HSCT, haematopoietic stem cell transplantation.
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(11 centres), central (4 centres) and southern (3 centres) Italy
(Fig. 1).
The mean age of the patients was 55 years (range, 3–63 years),
60% were males, and the underlying diseases were acute lymphatic
leukaemia (10.5%; n = 24), chronic lymphatic leukaemia (4.4%;
n = 10), acute myeloid leukaemia (32%; n = 73), chronic myeloid
leukaemia (0.9%; n = 2), hairy cell leukaemia (0.4%; n = 1),
lymphoma (22.8%; n = 52), multiple myeloma (12.7%; n = 29) and
other haematological malignancies (7.9%; n = 18); 40.8% (93/228) of
patients underwent HSCT (67.7%, n = 63, allogeneic; 27.9%, n = 26,
autologous). Prior to Aspergillus isolation, 40.4% (92/228) of
patients received a previous azole treatment as prophylaxis or
target therapy, 6 received treatment with liposomal amphotericin
B or echinocandins and 28 did not receive any antifungal treatment
before the fungal isolation. No information was available for the
other patients.
Information about smoking habits and working and recrea-
tional activity with soil exposure was limited: 26 of 44 respondents
were smokers and 22 handled soil. A total of 162 patients gave
information about their place of residence—94 (58%) reported
living in a rural area and 68 (42%) in an urban area.
The most frequently isolated species belonged to the section
Fumigati (45.9%), Nigri (20.9%), Flavi (16.8%) and Terrei (4.8%). A
detailed species distribution is reported in Table 1.Table 2
Azole-resistant Aspergillus isolates and patients demographic and clinical characteristic
Parameter Patient 1 
Aspergillus spp. A. awamori (section Nig
Specimen Nasal swab 
Reason for culture Diagnosis 
Aspergillosis Sinusitis 
Minimal inhibitory concentration (mg/L)
ITRA >16 
POSA 0.12 
VORI 0.5 
Cyp51A mutation Not known 
Gender, age (years) Male, 72 
Underlying disease Acute myeloid leukaem
Possible predisposing factors Gardening 
Antifungal administration prior to Aspergillus isolation Fluconazole 
Treatment after Aspergillus isolation Voriconazole 
Outcome at 6 months after isolation Alive 
HSCT, haematopoietic stem cell transplantation; ITRA, itraconazole; POSA, posaconazoThe screening for azole resistance revealed that 21 of 292 (7.2%)
isolates were potentially resistant—14 Aspergillus section Nigri, 6
Aspergillus section Fumigati and 1 Aspergillus section Flavi. The
broth microdilution method confirmed azole resistance in three
isolates from three patients—one A. fumigatus sensu stricto
(itraconazole MIC, 4 mg/L; posaconazole MIC, 0.5 mg/L), one A.
lentulus (section Fumigati, itraconazole MIC > 16 mg/L) and one
Aspergillus awamori (section Nigri, itraconazole MIC > 16 mg/L)
(Table 2). In Fig. 1, the places where the resistant strains were
isolated are reported.
The itraconazole resistance rate was 1% (3/292) considering all
Aspergillus spp. isolates and 1.48% (2/135) considering only
Aspergillus section Fumigati. The prevalence of azole resistance
among all the patients was 1.3% (3/228). The prevalence was 0.79%
(1/126), considering only patients harbouring A. fumigatus sensu
stricto isolates.
The A. fumigatus sensu stricto resistant strain was isolated from
one patient (male, 55 years old, lived in the countryside, smoker)
with myeloma who underwent autologous HSCT (Table 2). The
patient was diagnosed with probable pulmonary IA with a positive
galactomannan antigen in bronchoalveolar lavage. The patient had
received fluconazole prophylaxis and voriconazole as treatment
following Aspergillus isolation in culture. Molecular analysis
revealed a TR34/L98H mutation in the cyp51A gene. Microsatellite
analysis showed that this A. fumigatus clinical isolate was
genotypically distant from the environmental and clinical isolates
from other clinical strains from the same geographical area (Fig. 2).
Both A. lentulus and A. awamori isolates showed high MIC values
of itraconazole (MIC > 16 mg/L); A. lentulus also showed high
values of voriconazole (2 mg/L). More details regarding these
patients are shown in Table 2. Note that the patient with A.
awamori culture had gardening as a possible risk factor. Mutations
responsible for azole resistance are not known for these species
[27].
4. Discussion
A. fumigatus azole resistance, both in clinical and environmental
isolates, is widely studied and is a source of worldwide concern
because azole therapy can be compromised, especially in the most
critical patients, such as patients with haematological malignan-
cies. The main aim of this prospective multicentre cohort study
was to establish the prevalence of A. fumigatus azole-resistant
isolates in patients affected by haematological malignancies or
who had undergone HSCT, hospitalized in different Italian centres.
Azole resistance was identified in three patients infected or
colonized by an Aspergillus spp., resulting in a rate of 1.3%. The rates.
Patient 2 Patient 3
ri) A. fumigatus sensu stricto A. lentulus(section Fumigati)
Bronchoalveolar lavage Sputum
Diagnosis Surveillance
Probable pulmonary Colonization
4 >16
0.5 0.03
0.5 2
TR34/L98H Not known
Male, 55 Female, 63
ia Myeloma; auto- HSCT Severe aplastic anaemia
Living in countryside; smoking habit Nothing declared
Fluconazole None
Voriconazole None
Alive Died
le; VORI, voriconazole.
Fig. 2. Dendrogram from unweighted pair group method using arithmetic averages (UPGMA) clustering method based on Nei's genetic distance matrix for Aspergillus spp.
isolates genotyped at six SSR loci using the environmental and clinical azole-resistant A. fumigatus isolates from the same geographical area. *Environmental isolate.
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isolation. These results from Italy are similar to those of a
retrospective study conducted in a haematology department in the
Netherlands, where the triazole resistance rate was 1.2% [28] or
from a more recent German multicentre surveillance study that
reported 1.1% of episodes due to triazole-resistant A. fumigatus
among acute leukaemia patients [29].
Conversely, a higher rate has been reported in studies carried
out in haematology patients in Belgium (4.4%) [30], in the same
Netherlands study (27.9%) [18] and in Germany (29.6%) [31]. In
Italy, high azole resistance rates were previously reported in
different patient groups, such as cystic fibrosis patients (8.2%) [32],
or in two studies of a heterogeneous population of patients, 6.25%
and 2%, respectively [19,33].
As previously observed by Lestrade et al. [28], the varying
incidence rates for azole-resistant A. fumigatus might reflect a true
variation but may be as a result of differences in methodology—
namely, the ability to detect resistance relied on culture and thedominator that was used. To improve the detection of resistance,
the analysis of up to five distinct colonies is recommended so as not
to miss those that are triazole-resistant [34]. Unfortunately, this
more suitable practice was not always applicable because of
different guidelines adopted in the participating laboratories.
In addition, we observed the absence of a common protocol of
mycological surveillance for haematological patients among the
different hospitals participating in this study. Furthermore, the low
rate of Aspergillus in culture reported from some participating
centres may be due to prompt antifungal treatment following a
diagnosis of IA through indirect methods. All these factors—
indirect diagnosis, no surveillance, analysis of only one colony—
could have led us to underestimate triazole resistance.
The environmental origin of A. fumigatus triazole resistance,
linked to the TR34/L98H mutation, is now shared in the scientific
community and this mutation was found in different crops all over
the Italian territory [12]. Contrary to results of our previous studies
[19,32], in this survey no homology was highlighted by genetic
6 A. Prigitano et al. / Journal of Global Antimicrobial Resistance 22 (2020) xxx–xxxanalysis among the A. fumigatus sensu stricto strain and the
environmental or clinical strains previously isolated in the same
area. However, this observation is certainly limited by the analysis
of only a single isolate.
Finally, in the present study, we identified two cryptic triazole-
resistant species, one A. lentulus (section Fumigati), intrinsically
azole-resistant, and one A. awamori (section Nigri). This finding
highlights the importance of correct identification at the species
level to reach a rapid therapeutic decision and to understand the
shift towards other cryptic species quickly.
In conclusion, dedicated surveillance programs should be put in
place to have updated information on the local epidemiology and
consideration of the high rates of azole resistance in the local
environment.
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